CorMedix Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapeutic and diagnostic products aimed at addressing hospital-acquired infections and associated complications in high-risk patient populations. Founded in 1985 and headquartered in Montville, New Jersey, the company focuses on innovative approaches that seek to prevent bloodstream infections, thrombosis and inflammation related to the use of indwelling medical devices. Its research-driven platform combines antimicrobial, anticoagulant and anti-inflammatory mechanisms to target serious, often life-threatening conditions in hospitalized patients.
The company’s lead product candidate, Neutrolin®, is an investigational catheter lock solution designed to reduce the incidence of catheter-related bloodstream infections and catheter occlusions in patients requiring long-term central venous access. Neutrolin combines a proprietary formulation of anticoagulant and antimicrobial agents that is intended to inhibit microbial colonization on catheter surfaces while maintaining patency. In addition to Neutrolin, CorMedix is advancing complementary programs that explore novel anti-infective molecules and diagnostic assays aimed at early detection or prevention of device-related infections.
CorMedix has pursued regulatory interactions and clinical development in the United States and Europe, engaging with healthcare institutions and academic centers to conduct pivotal studies. The company has established strategic partnerships with contract research organizations and distribution networks to support manufacturing scale-up, clinical trial enrollment and future commercialization. By leveraging global expertise and compliance with stringent regulatory standards, CorMedix aims to provide healthcare providers with new tools to lower infection rates and improve patient outcomes in intensive care, oncology and hemodialysis settings.
CorMedix’s leadership team brings decades of combined experience in pharmaceutical development, clinical operations and regulatory affairs. Guided by a seasoned board of directors and scientific advisors, the company integrates expertise in infectious disease, critical care medicine and drug manufacturing. This multidisciplinary approach underpins CorMedix’s commitment to advancing its pipeline candidates toward regulatory approval and ultimately transforming care paradigms for patients at high risk of device-associated infections.
AI Generated. May Contain Errors.
Free CRMD Stock Alerts